- Home
- NDMO vs IMNM Comparison
NDMO vs IMNM Comparison
Compare NDMO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NDMO | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.7M | 2.8B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NDMO | IMNM |
|---|---|---|
| Price | $9.97 | $19.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 119.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.30 | $5.15 |
| 52 Week High | $10.82 | $27.65 |
Technical Indicators
Market Signals| Indicator | NDMO | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 36.28 |
| Support Level | $9.94 | $19.26 |
| Resistance Level | $10.43 | $22.57 |
| Average True Range (ATR) | 0.17 | 1.01 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 14.04 | 4.35 |
Price Performance
Historical ComparisonAbout NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.